Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels

European Journal of Heart Failure

Volumn 12, Issue 10, 2010, Pages 1092-1100

  Raposeiras Roubín, Sergio ^a   Rodiño Janeiro, Bruno K ^a   Grigorian Shamagian, Lilian ^a,b   Moure González, María ^a   Seoane Blanco, Ana ^a   Varela Román, Alfonso ^a   Alvarez, Ezequiel ^a,c   González Juanatey, José R ^a,c  

^a Instituto de Salud Carlos III   (Spain)

^b HOSPITAL DO MEIXOEIRO   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

(soluble) AGE receptor (s)RAGE ; Advanced glycation end products (AGE); Chronic heart failure; Coronary artery disease

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INSULIN; NITRATE; ORAL ANTIDIABETIC AGENT; SPIRONOLACTONE; STATIN;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX; VESSEL;

AGED; ALBUMINS; CHRONIC DISEASE; CONFIDENCE INTERVALS; CORONARY ARTERY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULAR FILTRATION RATE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEART FAILURE; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; ODDS RATIO; ROC CURVE; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC;

EID: 77957243199     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq117     Document Type: Article

References (30)

1. Grandhee SK, Monnier VM. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem 1991;266:11649-11653.
2. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 1994;14:1521-1528.
3. Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001;56:1-21.
4. Brownlee M. Negative consequences of glycation. Metabolism 2000;49:9-13.
5. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T, Yamasaki Y. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients. Diab Vasc Dis Res 2008; 5:190-197.
6. Hartog JW, Voors AA, Bakker SJ, Smit AJ, van Veldhuisen DJ. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail 2007;9:1146-1155.
7. Van Heerebeek L, Paulus WJ. The dialogue between diabetes and diastole. Eur J Heart Fail 2009;11:3-5.
8. Bucciarelli LG, Kaneko M, Ananthakrishnan R, Harja E, Lee LK, Hwang YC, Lerner S, Bakr S, Li Q, Lu Y, Song F, Qu W, Gomez T, Zou YS, Yan SF, Schmidt AM, Ramasamy R. Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation 2006;113:1226-1234.
9. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003;108:1070-1077.
10. Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SR, Cooper ME, Allen TJ. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004;53:1813-1823.
11. Santilli F, Vazzana N, Bucciarelli LG, Davi G. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem 2009;16:940-952.
12. Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M, Geroldi D. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005;25: 1032-1037.
13. Lindsey JB, de Lemos JA, Cipollone F, Ayers CR, Rohatgi A, Morrow DA, Khera A, McGuire DK. Association between circulating soluble receptor for advanced glycation end products (sRAGE) and atherosclerosis: observations from the Dallas heart study. Diabetes Care 2009;32:1218-1220.
14. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 2006;13:1971-1978.
15. Lu L, Pu LJ, Zhang Q, Wang LJ, Kang S, Zhang RY, Chen QJ, Wang JG, De Caterina R, Shen WF. Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. Atherosclerosis 2009;206:540-545.
16. Hartog JW, Voors AA, Schalkwijk CG, Scheijen J, Smilde TD, Damman K, Bakker SJ, Smit AJ, van Veldhuisen DJ. Clinical and prognostic value of advanced glycation end-products in chronic heart failure. Eur Heart J 2007;28:2879-2885.
17. Smit AJ, Hartog JW, Voors AA, van Veldhuisen DJ. Advanced glycation endpro-ducts in chronic heart failure. Ann N Y Acad Sci 2008;1126:225-230.
18. Koyama Y, Takeishi Y, Niizeki T, Suzuki S, Kitahara T, Sasaki T, Kubota I. Soluble Receptor for advanced glycation end products (RAGE) is a prognostic factor for heart failure. J Card Fail 2008;14:133-139.
19. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-989.
20. Levey AS. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266.
21. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-254
22. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004;27(Suppl 1): S5-S10.
23. Munch G, Keis R, Wessels A, Riederer P, Bahner U, Heidland A, Niwa T, Lemke HD, Schinzel R. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 1997;35:669-677.
24. Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, Rong LL, Jenkins DG, Stein G, Schmidt AM, Yan SF. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2006;185:70-77.
25. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998;4:1025-1031.
26. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, Sato A, Imaizumi T. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev 2007;23:368-371.
27. Yan XX, Lu L, Peng WH, Wang LJ, Zhang Q, Zhang RY, Chen QJ, Shen WF. Increased serum HMGB1 level is associated with coronary artery disease in non-diabetic and type 2 diabetic patients. Atherosclerosis 2008;205:544-548.
28. Nielsen JM, Kristiansen SB, Norregaard R, Andersen CL, Denner L, Nielsen TT, Flyvbjerg A, Botker HE. Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice. Eur J Heart Fail 2009;11:638-647.
29. Li J, Solus J, Chen Q, Rho YH, Milne G, Stein CM, Darbar D. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 2009;7:438-444.
30. Ramasamy R, Yan SF, Schmidt AM. RAGE: therapeutic target and biomarker of the inflammatory response-the evidence mounts. J Leukoc Biol 2009;86:505-512.